Last Price
3.02
Today's Change
-0.07 (2.26%)
Day's Change
2.88 - 3.16
Trading Volume
59,669
Market Cap
10 Million
Shares Outstanding
33 Million
Avg Volume
121,385
Avg Price (50 Days)
4.92
Avg Price (200 Days)
3.80
PE Ratio
-0.47
EPS
-6.44
Earnings Announcement
16-Dec-2024
Previous Close
3.09
Open
3.11
Day's Range
2.885 - 3.16
Year Range
1.9 - 15.8
Trading Volume
59,686
1 Day Change
-2.27%
5 Day Change
-14.69%
1 Month Change
-45.39%
3 Month Change
-7.08%
6 Month Change
12.69%
Ytd Change
-32.89%
1 Year Change
-21.56%
3 Year Change
-96.03%
5 Year Change
-92.89%
10 Year Change
-96.92%
Max Change
-99.43%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.